We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Investigational Device Monitors Venous Waveform

By HospiMedica International staff writers
Posted on 05 Jul 2021
A novel non-invasive venous waveform analysis (NIVA) device provides a proprietary score that corresponds to pulmonary capillary wedge pressure (PCWP).

The VoluMetrix (Nashville, TN, USA) NIVA HF device is designed to capture the venous waveform, an energy-based signal generated by the heart and respiratory activity that reflects numerous physiologic conditions, including pulse rate, respiration, and intravascular and extravascular dynamics. More...
It serves as a non-invasive indicator of volume status and the presence of congestion in patients with heart failure (HF).

The device is based on a non-invasive wrist sensor that identifies multiple frequencies that are first deconstructed by mapping individual amplitudes within a patient's waveform, and subsequently decoded by a proprietary algorithm. The result is the NIVA score, which provides cardiologists and other healthcare professionals (and their patients) with a simple measure that parallels to PCWP, a well-recognized and clinically relevant assessment of volume status. Using PCWP to evaluate blood volume status is especially important when fluids are administered during hypotensive shock.

“NIVA HF is the culmination of our organization's talent, intellect, passion, and hard work. It represents the first of many potential vehicles for our NIVA vital monitoring technology,” said Kyle Hocking, PhD, President and CEO of VoluMetrix. “Ultimately, our mission is to improve the care experience for as many heart failure patients as possible, as quickly as possible.”

PCWP provides an indirect estimate of left atrial pressure (LAP), and can help quantify the severity of left ventricular failure and the degree of mitral valve stenosis, aortic valve stenosis and regurgitation, mitral regurgitation, and pulmonary hypertension. By measuring PCWP, the physician can titrate the dose of diuretic and other drugs that are used to reduce pulmonary venous and capillary pressure, and thereby reduce pulmonary edema.

Related Links:
VoluMetrix


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
X-Ray System
Leonardo DR mini III
Medical Monitor
SILENIO D
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.